N-biarylamides
AssigneeBayer Intellectual Property GmbH
InventorsTimo Fleβner, Frank-Gerhard Böβ, Frank-Thorsten Hafner, Joachim Luithle, Christoph Methfessel, Leila Telan
Life of this patent
Estimating the term…
Abstract
The invention relates to N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improvement in cognition, concentration power, learning power and/or memory.
Claims7
A method for treating impairments of perception, concentration, learning and/or memory in a patient suffering from Alzheimer's disease or schizophrenia, comprising administering to the patient a compound represented by Formula (I):
- in an amount effective to stimulate an alpha7 nicotinic acetylcholine receptor (α7 nAChR), in which
- R1 is a group of the formula —NR2—CO—NR3R4, —NR2—CO—CO—OR5, —NH—SO2R6, —SO2NHR7 or —NH—CO—R8, where
- R2 is hydrogen or C1-C6-alkyl,
- R3 and R4 are independently of one another hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl or phenyl, which is optionally substituted by up to 3 radicals independently of one another selected from the group of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, trifluoromethyl and trifluoromethoxy, or
- R3 and R4 together with the nitrogen atom to which they are bonded form a 5- to 6-membered heterocyclyl,
- R5 is hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl or aryl, where C1-C6-alkyl is optionally substituted by aryl,
- R6 is C1-C6-alkyl, C3-C8-cycloalkyl, 5- to 6-membered heterocyclyl, aryl or 5- to 6-membered heteroaryl, where C1-C6-alkyl is optionally substituted by aryl,
- R7 is hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl, 5- to 6-membered heterocyclyl, aryl or 5- to 6-membered heteroaryl, where C1-C6-alkyl is optionally substituted by aryl,
- R8 is C3-C8-cycloalkyl, C1-C6-alkyl or phenyl, where C1-C6-alkyl is substituted by C1-C6-alkoxy and phenyl by 1 to 3 radicals independently of one another selected from the group of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, trifluoromethyl and trifluoromethoxy,
- or a salt thereof.
A method for treating impairments of perception, concentration, learning and/or memory in a patient suffering from Alzheimer' s disease or schizophrenia, comprising administering to the patient a pharmaceutical composition comprising:
- i) a compound represented by Formula (I):
- in an amount effective to stimulate an alpha7 nicotinic acetylcholine receptor (α7 nAChR),
- in which
- R1 is a group of the formula —NR2—CO—NR3R4, —NR2—CO—CO—OR5, —NH—SO2R6, —SO2NHR7 or —NH—CO—R8, where
- R2 is hydrogen or C1-C6-alkyl,
- R3 and R4 are independently of one another hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl or phenyl, which is optionally substituted by up to 3 radicals independently of one another selected from the group of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, trifluoromethyl and trifluoromethoxy, or
- R3 and R4 together with the nitrogen atom to which they are bonded form a 5- to 6-membered heterocyclyl,
- R5 is hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl or aryl, where C1-C6-alkyl is optionally substituted by aryl,
- R6 is C1-C6-alkyl, C3-C8-cycloalkyl, 5- to 6-membered heterocyclyl, aryl or 5-to 6-membered heteroaryl, where C1-C6-alkyl is optionally substituted by aryl,
- R7 is hydrogen, C1-C6-alkyl, C3-C8-cycloalkyl, 5- to 6-membered heterocyclyl, aryl or 5- to 6-membered heteroaryl, where C1-C6-alkyl is optionally substituted by aryl,
- R8 is C3-C8-cycloalkyl, C1-C6-alkyl or phenyl, where C1-C6-alkyl is substituted by C1-C6-alkoxy and phenyl by 1 to 3 radicals independently of one another selected from the group of halogen, cyano, C1-C6-alkyl, C1-C6-alkoxy, trifluoromethyl and trifluoromethoxy,
- or a salt thereof;
- and
- ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.